missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human ANKRD12 (aa 374-477) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (78%), Rat (78%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-59258 (PA5-59258. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
This gene encodes a member of the ankyrin repeats-containing cofactor family. These proteins may inhibit the transcriptional activity of nuclear receptors through the recruitment of histone deacetylases. The encoded protein interacts with p160 coactivators and also represses transcription mediated by the coactivator alteration/deficiency in activation 3 (ADA3). Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.
Specifications
Specifications
| Accession Number | Q6UB98 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 23253 |
| Name | Human ANKRD12 (aa 374-477) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | 2900001A12Rik; AI447928; ANCO1; ANCO2; ANCO-2; Ankrd12; ankyrin repeat domain 12; ankyrin repeat domain-containing 12-like protein; ankyrin repeat domain-containing protein 12; Ankyrin repeat domain-containing protein 12-like protein; ankyrin repeat-containing cofactor 2; AV347965; GAC-1; GAC-1 protein; KIAA0874; mKIAA0874; Nbla00144 |
| Common Name | ANKRD12 |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction